United States · Platforms & data · MarketBeat

Climb Bio (NASDAQ:CLYM) Stock Gets Downgrade from Wall Street Zen

Published by MarketBeat · United States 48 min ago

Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

Wall Street Zen cut Climb Bio from a "hold" rating to a "sell" rating in a report on Sunday.

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

SocGen's Albert Edwards warns liquidity squeeze, inflation threaten AI stock rally

The Motley Fool

Which Real Estate ETF Is the Better Buy: State Street’s REIT Fund RWR or Global Fund RWO?

China’s hottest stocks these days have one thing in common: names that sound like sheep

Bessent says Nvidia must ’go outside the company’ to find new CEO

Goldman Sachs reset S&P 500 price target for 2027

Active ETFs are surging in 2026: They hold an edge in 3 scenarios